JOHN KIRKWOOD to United States Food and Drug Administration
This is a "connection" page, showing publications JOHN KIRKWOOD has written about United States Food and Drug Administration.
Connection Strength
0.209
-
IFN-a in the treatment of melanoma. J Immunol. 2012 Oct 15; 189(8):3789-93.
Score: 0.093
-
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J Immunother Cancer. 2018 05 14; 6(1):35.
Score: 0.034
-
Anti-PD-1 antibody treatment for melanoma. Lancet Oncol. 2018 05; 19(5):e219.
Score: 0.034
-
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med. 2009 Jun 17; 7:45.
Score: 0.018
-
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med. 2008 Dec 23; 6:81.
Score: 0.018
-
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother. 2002 Mar-Apr; 25(2):97-138.
Score: 0.011